Actelion hits six-year high after favorable FDA approval for drug

Actelion hits six-year high after favorable FDA approval for drug

"Opsumit's FDA approved label is close to a best case outcome, in our view," said Deutsche Bank analyst Richard Parkes, who has a 'buy' rating on the stock and raised his price target to 72 francs from 70 francs. Shares in Actelion were up 5.3 percent

3
Like
Save

Comments

Write a comment

*